Molecular and clinical characterization of TIM-3 in glioma through 1,024 samples

Tim-3 and its role in regulating anti-tumor immunity

(2017) Madhumita Das et al.   IMMUNOLOGICAL REVIEWS

CGCG clinical practice guidelines for the management of adult diffuse gliomas

(2016) Tao Jiang et al.   CANCER LETTERS

Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas

(2016) Jennifer E. Kim et al.   CLINICAL CANCER RESEARCH

Upregulation of T-cell Immunoglobulin and Mucin-Domain Containing-3 (Tim-3) in Monocytes/Macrophages Associates with Gastric Cancer Progression

(2016) Zhenxin Wang et al.   IMMUNOLOGICAL INVESTIGATIONS

The comparison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomas

(2016) Hao-Yuan Wang et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

PD-1 says goodbye, TIM-3 says hello

(2016) Diana Romero   Nature Reviews Clinical Oncology

Molecular and clinical characterization of PD-L1 expression at transcriptional level via 976 samples of brain glioma

(2016) Zheng Wang et al.   OncoImmunology

Progress in the application of molecular biomarkers in gliomas

(2015) Jing Wang et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Increased Tim-3 expression in peripheral NK cells predicts a poorer prognosis and Tim-3 blockade improves NK cell-mediated cytotoxicity in human lung adenocarcinoma

(2015) Liyun Xu et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Programmed death-ligand 1 (PD-L1) may play a role in malignant glioma infiltration

(2015) Lei Zhang et al.   MEDICAL HYPOTHESES

Structural and functional features of central nervous system lymphatic vessels

(2015) Antoine Louveau et al.   NATURE

Tim-3 expression represents dysfunctional tumor infiltrating T cells in renal cell carcinoma

(2015) Chen Cai et al.   WORLD JOURNAL OF UROLOGY

Tim-3 protects decidual stromal cells from toll-like receptor-mediated apoptosis and inflammatory reactions and promotes Th2 bias at the maternal-fetal interface

(2015) SongCun Wang et al.   Scientific Reports

Focal Radiation Therapy Combined with 4-1BB Activation and CTLA-4 Blockade Yields Long-Term Survival and a Protective Antigen-Specific Memory Response in a Murine Glioma Model

(2014) Zineb Belcaid et al.   PLoS One

Tumor-induced senescent T cells promote the secretion of pro-inflammatory cytokines and angiogenic factors by human monocytes/macrophages through a mechanism that involves Tim-3 and CD40L

(2014) M C Ramello et al.   Cell Death & Disease

Tim-3: An Emerging Target in the Cancer Immunotherapy Landscape

(2014) A. C. Anderson   Cancer Immunology Research

A Special Population of Regulatory T Cells Potentiates Muscle Repair

(2013) Dalia Burzyn et al.   CELL

TIM-3 as a molecular switch for tumor escape from innate immunity

(2013) Fabrizio Mattei et al.   Frontiers in Immunology

TIM3+FOXP3+regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer

(2013) Kaori Sakuishi et al.   OncoImmunology

PPAR-γ is a major driver of the accumulation and phenotype of adipose tissue Treg cells

(2012) Daniela Cipolletta et al.   NATURE

Bat3 promotes T cell responses and autoimmunity by repressing Tim-3–mediated cell death and exhaustion

(2012) Manu Rangachari et al.   NATURE MEDICINE

Immunotherapy for Glioma

(2012) Seunggu J. Han et al.   NEUROSURGERY CLINICS OF NORTH AMERICA

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

TIM-3 Expression Characterizes Regulatory T Cells in Tumor Tissues and Is Associated with Lung Cancer Progression

(2012) Xin Gao et al.   PLoS One

Correlation of IDH1 Mutation with Clinicopathologic Factors and Prognosis in Primary Glioblastoma: A Report of 118 Patients from China

(2012) Wei Yan et al.   PLoS One

Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia

(2011) Q. Zhou et al.   BLOOD

Tim-3 regulates pro- and anti-inflammatory cytokine expression in human CD14+ monocytes

(2011) Ying Zhang et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker

(2011) M. Jan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Exciting New Advances in Neuro-Oncology: The Avenue to a Cure for Malignant Glioma

(2010) E. G. Van Meir et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1

(2010) Roel G.W. Verhaak et al.   CANCER CELL

TIM-3 Is a Promising Target to Selectively Kill Acute Myeloid Leukemia Stem Cells

(2010) Yoshikane Kikushige et al.   Cell Stem Cell

Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+T cell dysfunction in melanoma patients

(2010) Julien Fourcade et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Involvement of T cell Ig Mucin-3 (Tim-3) in the negative regulation of inflammatory bowel disease

(2009) Xia Li et al.   CLINICAL IMMUNOLOGY

IDH1andIDH2Mutations in Gliomas

(2009) Hai Yan et al.   NEW ENGLAND JOURNAL OF MEDICINE